- ÃßÈÄ °³ÀÎÁ¤º¸ ¾÷µ¥ÀÌÆ®¸¦ À§ÇØ, ÀÔ·ÂÇϽŠID (À̸ÞÀÏ ÁÖ¼Ò)¿Í ÆÐ½º¿öµå¸¦ ¹Ýµå½Ã ±â¾ïÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
ID (À̸ÞÀÏ ÁÖ¼Ò)
*
ÆÐ ½º ¿ö µå
*
(4~8ÀÚ ÀÌÇÏ ¿µ¹®À̳ª ¼ýÀÚÀÇ Á¶ÇÕ)
ÆÐ ½º ¿ö µå È® ÀÎ
*
¼º ¸í
*
ȸ »ç ¸í
*
ºÎ ¼ ¸í
Á÷ À§
¿ì Æí ¹ø È£
*
-
ȸ »ç ÁÖ ¼Ò
*
»ó ¼¼ ÁÖ ¼Ò
*
Àü È
*
¼±ÅÃ
02
031
032
033
041
042
043
051
052
053
054
055
061
062
063
064
080
-
¿¹) 02-508-4217
ÆÑ ½º
¼±ÅÃ
02
031
032
033
041
042
043
051
052
053
054
055
061
062
063
064
080
-
¿¹) 02-508-4218
ÇÚ µå Æù
*
¼±ÅÃ
010
011
016
017
018
019
-
- ¸íÂû¿¡ º¸¿©Áú ³»¿ëÀÔ´Ï´Ù.
¿µ¹®À¸·Î
ÀÛ¼ºÇÏ¿©Áֽñ⠹ٶø´Ï´Ù
Name (¼º¸í)
*
First Name
¿¹) ±æµ¿ ¡æ Gil-dong
Last Name
¿¹) È« ¡æ Hong
Organization (¼Ò¼Ó)
*
10. 8
(¼ö)
°³È¸½Ä & ±âÁ¶¿¬¼³
Micro/Nano-
biotechnology
Technology
Licensing
¹é½Å
Ubiquitous
Healthcare
13:30-15:30
Micro/Nano-fluidics Technology
of UK/KOREA
13:30-15:00
Preparation of
Successful Licensing
13:30-14:30
Ưº°°¿¬
Hepatitis C Virus
13:30-15:00
u-Health as Emerging Healthcare Service
15:50-17:50
Micro/Nano-biotechnology
of UK/KOREA I
15:20-16:50
Case Studies - Strategies for
Successful Technology Transfer
14:30-16:00
¾Ï¹é½ÅÀÇ ÇٽɼººÐ°ú
Ãֽŵ¿Çâ
16:20-17:50
¹é½Å°³¹ßÀÇ »õ·Î¿î
µ¿Çâ
15:20-16:50
Technologies and Applications for
u-Healthcare
10. 9
(¸ñ)
Biorefinery
Micro/Nano-
biotechnology
Medical
Devices
½º¸¶Æ® ¾à¹°
Àü´Þ Àü·«
Business
Development
10:00-11:30
Processing of Lignocellulosic Biomass for Biorefinery
10:00-12:00
Micro/Nano-
biotechnology of UK/KOREA II
10:00-11:30
ÀÇ·á¿ë
ÀÓÇöõÆ®¸¦ À§ÇÑ »ýüÀûÇÕ¼ºÀç·á
10:00-11:30
¾à¹°Àü´Þ È¿À²ÀÇ
ÃÖÀûÈ
10:00-11:00
Ưº°°¿¬
Merck's Partnering
Strategy
in the Asia-Pacific
Region
11:00-12:30
Benchmarking Globally
Commercialized
Innovative Therapeutics
& Technologies
13:30-15:00
Microbial Catalysis
and Engineering
13:30-15:00
½ÉÇ÷°ü°è µð¹ÙÀ̽º
13:30-15:00
ÁúȯºÎÀ§·ÎÀÇ ¾à¹°
Àü´Þ Àü·«
13:30-15:00
Solutions to
Complicated Dilemmas of Funding-investment
Opportunities & Business
Development
15:20-16:50
Enzyme Catalysis
and Engineering
15:20-16:50
±Ù°ñ°Ý°è ÀÓÇöõÆ®
15:20-16:50
¾à¹°Àü´Þ ±â¼úÀÇ
ÃÖ±ÙÁøº¸
15:20-16:50
Technological
Innovation Strategy
for Biotechnology
10. 10
(±Ý)
Àç»ýÀÇÇÐÀÇ
ÃÖ±ÙÁøº¸
Regulatory
and GMP
Compliance
Therapeutic
Antibody
Botanical
New Drug
Development
Clinical Drug
Development
10:00-11:30
°æÁ¶Á÷ Àç»ýÀÇÇÐ
10:00-11:30
Regulatory Update
10:00-11:30
Recent Advances in
Therapeutic Antibody
R&D
10:00-11:30
õ¿¬¹° ¿¬±¸
°³¹ßÀü·«
10:00-11:30
Enhancing
Competitiveness
in Multinational Clinical
Trials
13:30-15:00
¿¬Á¶Á÷ Àç»ýÀÇÇÐ
13:30-15:00
GMP Compliance
13:30-15:00
Process Development of
Therapeutic Antibodies
13:30-15:00
õ¿¬¹° °³¹ß
¹× ¸¶ÄÉÆÃ
13:30-15:00
Clinical Trial Expert
Education and Training I
15:20-16:50
±Û·Î¹ú ¸¶ÄÏÀ» À§ÇÑ
ÃÖ±Ù »ó¿ëÈ µ¿Çâ
15:20-16:50
Quality Control
and Quality
Assurance
15:20-16:50
Forecasts by Industries in
Therapeutic Antibody
Development
15:20-16:50
õ¿¬¹° °³¹ß
ÇöȲ ¹× Àü¸Á
15:20-16:50
Clinical Trial Expert
Education and Training II
±¸ ºÐ
3ÀÏ ÆÐ½º
1ÀÏ ÆÐ½º
10¿ù 8ÀÏ
10¿ù 9ÀÏ
10¿ù 10ÀÏ
9¿ù 26ÀÏ ±îÁö
9¿ù 27ÀÏ ÀÌÈÄ
9¿ù 26ÀÏ ±îÁö
9¿ù 27ÀÏ ÀÌÈÄ
ÀÏ ¹Ý
88,000¿ø
110,000¿ø
44,000¿ø
55,000¿ø
´Ü ü
44,000¿ø
55,000¿ø
0
22,000¿ø
28,000¿ø
ÇÐ »ý
44,000¿ø
55,000¿ø
0
22,000¿ø
28,000¿ø
Free Pass
* ƼÄÏÀÇ ÀϷùøÈ£¸¦ ³Ö¾î ÁÖ¼¼¿ä.
µî·Ïºñ ÃѾ×:
¿ø
¡Ø ÇлýÀÇ °æ¿ì, ÇлýÁõ »çº»À» À̸ÞÀÏ(bioconf@ibimp.com)À̳ª ÆÑ½º(02-508-4218)¸¦ ÀÌ¿ëÇÏ¿© ÄÁÆÛ·±½º »ç¹«±¹À¸·Î
¼ÛºÎÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
¡Ø ´ÜüÇÒÀÎÀº 20ÀÎ ÀÌ»óÀÌ µ¿½Ã¿¡ µî·ÏÇϽô °æ¿ì¿¡ ÇÑÇÕ´Ï´Ù.
- µî·Ï ½Åû ÈÄ, µî·Ïºñ ¿Ï³³ÀÌ ÀÌ·ç¾îÁ®¾ß µî·Ï󸮰¡ ¿Ï·áµË´Ï´Ù.
- ½Å¿ëÄ«µå °áÁ¦ ¼±Åà ½Ã ÆË¾÷À» Ç×»ó Çã¿ë(µµ±¸-ÆË¾÷ Â÷´Ü-ÆË¾÷ Â÷´Ü »ç¿ë ¾ÈÇÔ)À¸·Î º¯°æÇÏ¿© Áֽñ⠹ٶó¸ç,
Windows XP SP2 ÀÌ»óÀÇ OS¸¦ »ç¿ëÇϽô ºÐµé²²¼´Â ½Å¿ëÄ«µå °áÁ¦ ½Ã â »ó´Ü¿¡ ³ë¶õ»ö ¹Ù°¡ ³ª¿À¸é
Active X ÄÁÆ®·Ñ ¼³Ä¡ Çã¿ëÀ» ¼±ÅÃÇØÁֽñ⠹ٶø´Ï´Ù.
°á Á¦ ±Ý ¾×
¿ø
°á Á¦ ¹æ ¹ý
°áÁ¦¹æ¹ý ¼±ÅÃ
½Å¿ëÄ«µå °áÁ¦
¹«ÅëÀå ÀÔ±Ý
Free Pass
ÀÔ ±Ý ÀÚ ¼º ¸í
*
ÀÔ ±Ý ¿¹ Á¤ ÀÏ
*
- °è»ê¼ÀÇ ¹ßÇàÀ» ¿øÇϽô ºÐÀº ¾Æ·¡¿¡ Ç¥½ÃÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
¿¹, ÇÊ¿äÇÕ´Ï´Ù.
- »ç¾÷ÀÚ µî·Ï¹øÈ£
-
-
- ȸ»ç¸í
- ´ëÇ¥ÀÚ¸í
- »ç¾÷Àå¼ÒÀçÁö
- ¾÷ÅÂ
- Á¾¸ñ
- ÀüÇÏ½Ç ¸»¾¸
¾Æ´Ï¿ä, ÇÊ¿äÇÏÁö ¾Ê½À´Ï´Ù.
- ¿µ¼öÁõÀÇ ¹ßÇàÀ» ¿øÇϽô ºÐÀº ¾Æ·¡¿¡ Ç¥½ÃÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
¿¹, ÇÊ¿äÇÕ´Ï´Ù.
¾Æ´Ï¿ä, ÇÊ¿äÇÏÁö ¾Ê½À´Ï´Ù.
- Âü¼®È®ÀÎÁõÀÇ ¹ß±ÞÀ» ¿øÇϽô ºÐÀº ¾Æ·¡¿¡ Ç¥½ÃÇÏ¿© Áֽñ⠹ٶø´Ï´Ù.
¿¹, ÇÊ¿äÇÕ´Ï´Ù.
¾Æ´Ï¿ä, ÇÊ¿äÇÏÁö ¾Ê½À´Ï´Ù.